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Background: The aim of this diploma thesis was to describe the origin and pathophysiology of 
cholesterol metabolism and to summarize the findings concerning the current 
pharmacotherapy of hypercholesterolemia. 
Main findings: High cholesterol bothers most of the adult population. Hypercholesterolemia 
is the major risk factor for atherosclerosis. If it is not treated it is considered to be a risk factor 
of cardiovascular diseases. For instance, myocardial infarction, angina pectoris and stroke. In 
addition to genetically acquired dyslipidemias, some diseases and drugs can increase 
cholesterol levels. It is important to warn patients first and foremost about following the given 
regime and dietary measures. If these measures don´t work, pharmacotherapy is indicated, 
which is currently at a high level, and there are enough drugs that lower the cholesterol. 
Conclusions: At present, we still have new substances available that, in combination with 
already established pharmacotherapy (statins, fibrates, ezetimibe), should lower cholesterol 
levels to the required values. These include anti-PCSK9 monoclonal antibodies, bempedoic 
acid, lomitapide, antisense oligonucleotides, anacetrapib, inclisiran and evinacumab. 
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